Category: MS Research Study and Reports

Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis

December 2024 The DOT-MS Randomized Clinical Trial Full article including the research team JAMA Neurol. Published online December 9, 2024. doi:10.1001/jamaneurol.2024.4164…

Stuart Schlossman

New Study Indicates MS May Worsen During Menopause

Researchers at the University of California – San Francisco found that menopause onset is associated with increased functional decline and…

Stuart Schlossman

Smoldering MS: the real MS becomes a tractable problem

Tolebrutinib, a second-generation BTK inhibitor, is the first to show a reduction in disability accumulation in non-relapsing secondary progressive MS…

Stuart Schlossman

Featured image for “2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MD”

2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MD

For those not sure the reason for this criteria, is it to help doctors Diagnose MS Author(s): Peter A. Calabresi,…

Stuart Schlossman

Featured image for “Help Make an IMPACT on Future MS Treatments”

Help Make an IMPACT on Future MS Treatments

Dear Potential Participant, My name is Tanisha Prater. I am completing a doctoral degree in health sciences at A.T. Still…

Stuart Schlossman

Featured image for “The Effect of Seasonal Changes on Multiple Sclerosis”

The Effect of Seasonal Changes on Multiple Sclerosis

Do you experience more MS symptoms in some seasons than others? Many of us do, says the blogger Trevis Gleason,…

Stuart Schlossman

Featured image for “A Case Study in Neurotherapeutic Clinical Trial Design and Conduct”

A Case Study in Neurotherapeutic Clinical Trial Design and Conduct

September 2024 New phase 1 trial showcases Neurological Institute’s interdisciplinary study capabilities Early this summer, Cleveland Clinic researchers enrolled the…

Stuart Schlossman

Featured image for “Let’s Move From Categorizing MS by Clinical Phenotype to Underlying Disease Mechanisms”

Let’s Move From Categorizing MS by Clinical Phenotype to Underlying Disease Mechanisms

September 19, 2024 – Meaningful characterization is critical to advancing research and care, review authors contend The currently used phenotypic…

Stuart Schlossman

Featured image for “Could Serum Neurofilament Light (sNFL) Chain Level Help Guide MS Management?”

Could Serum Neurofilament Light (sNFL) Chain Level Help Guide MS Management?

April 2024 Perhaps, with caveats: sNfL elevation has low sensitivity and lags MRI activity by at least a month Serum…

Stuart Schlossman

Factors Influencing Time Delays in Initiating High-Efficacy Treatment in Multiple Sclerosis: Valentin Krüger, MD

September 19, 2024 By Valentin Krüger, MD / Isabella Ciccone, MPH — Fact checked by Marco Meglio The neurology resident at the…

Stuart Schlossman

Categories

Latest Blog Posts